PMID- 9681590
OWN - NLM
STAT- MEDLINE
DCOM- 19980916
LR  - 20131121
IS  - 1323-1316 (Print)
IS  - 1323-1316 (Linking)
VI  - 52
IP  - 3
DP  - 1998 Jun
TI  - Widespread expression of Fos protein induced by acute haloperidol administration 
      in the rat brain.
PG  - 353-9
AB  - The effect of acute haloperidol administration on Fos protein expression was 
      examined immunohistochemically in discrete regions of the rat brain. Male Wistar 
      rats were injected subcutaneously (s.c.) with 0.1, 0.25, or 1.0 mg/kg of 
      haloperidol. Two h after the injection, the rats were perfused, and the numbers 
      of Fos immunoreactive neurons were counted in 24 brain regions. In contrast to 
      the limited changes in Fos immunoreactivity at the low dose of haloperidol (0.1 
      mg/kg), the moderate dose (0.25 mg/kg) induced widespread increases in 
      Fos-positive neurons in the rat brain. Large increases were produced in the 
      caudate-putamen, nucleus accumbens, central amygdaloid nucleus, dorsomedial 
      hypothalamic nucleus, hippocampus CA1 and substantia nigra pars compacta. 
      Moderate increases were observed in the entorhinal cortex, lateral septum, 
      lateral habenula, lateral amygdaloid nucleus, dentate gyrus, and mesencephalic 
      central grey. Mild increases were induced in the anterior cingulate, temporal, 
      occipital and perirhinal cortex, and central medial thalamic nucleus. The 
      distribution of changes in Fos immunoreactivity at the high dose of haloperidol 
      (1.0 mg/kg) were comparable to their distribution at the moderate dose. These 
      findings indicate that the effect of acute haloperidol on Fos expression is 
      widely distributed in the rat brain beyond the previously known dopamine-rich 
      areas at the dose which produces plasma levels equivalent to those within the 
      therapeutic range used clinically in humans. Further studies on the effects of 
      chronic antipsychotic treatment are needed in order to identify the sites of the 
      therapeutic action of antipsychotic drugs.
FAU - Suzuki, M
AU  - Suzuki M
AD  - Department of Neuropsychiatry, Faculty of Medicine, Toyama Medical and 
      Pharmaceutical University, Sugitani, Japan.
FAU - Sun, Y J
AU  - Sun YJ
FAU - Murata, M
AU  - Murata M
FAU - Kurachi, M
AU  - Kurachi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/*pharmacology
MH  - Brain/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Haloperidol/*pharmacology
MH  - Immunohistochemistry
MH  - Injections, Subcutaneous
MH  - Male
MH  - Neurons/chemistry/drug effects
MH  - Proto-Oncogene Proteins c-fos/*biosynthesis/drug effects
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/07/29 00:00
MHDA- 1998/07/29 00:01
CRDT- 1998/07/29 00:00
PHST- 1998/07/29 00:00 [pubmed]
PHST- 1998/07/29 00:01 [medline]
PHST- 1998/07/29 00:00 [entrez]
AID - 10.1046/j.1440-1819.1998.00391.x [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 1998 Jun;52(3):353-9. doi: 
      10.1046/j.1440-1819.1998.00391.x.